Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 5Lymphoid 3Gastrointestinal 3Plasma cell 2NET 2Endocrine 2Breast 2Other hematologic neoplasm 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Neuroendocrine Tumors 2

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Positron Emission Tomography Computed Tomography × NET × Clear all
NCT03271281 2022-06-30

PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2

Rigshospitalet, Denmark

Phase 2 Completed
113 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03278275 2022-06-30

PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105

Rigshospitalet, Denmark

Phase 2 Completed
116 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡